000132470 001__ 132470
000132470 005__ 20240229105018.0
000132470 0247_ $$2doi$$a10.1002/ijc.31164
000132470 0247_ $$2pmid$$apmid:29159934
000132470 0247_ $$2pmc$$apmc:PMC5805613
000132470 0247_ $$2ISSN$$a0020-7136
000132470 0247_ $$2ISSN$$a1097-0215
000132470 0247_ $$2altmetric$$aaltmetric:29277867
000132470 037__ $$aDKFZ-2018-00158
000132470 041__ $$aeng
000132470 082__ $$a610
000132470 1001_ $$00000-0002-1426-8505$$aFortner, Renée T$$b0$$eFirst author
000132470 245__ $$aOvarian cancer early detection by circulating CA125 in the context of anti-CA125 autoantibody levels: Results from the EPIC cohort.
000132470 260__ $$aBognor Regis$$bWiley-Liss$$c2018
000132470 3367_ $$2DRIVER$$aarticle
000132470 3367_ $$2DataCite$$aOutput Types/Journal article
000132470 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1521445756_7049
000132470 3367_ $$2BibTeX$$aARTICLE
000132470 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000132470 3367_ $$00$$2EndNote$$aJournal Article
000132470 520__ $$aCA125 is the best ovarian cancer early detection marker to date; however, sensitivity is limited and complementary markers are required to improve discrimination between ovarian cancer cases and non-cases. Anti-CA125 autoantibodies are observed in circulation. Our objective was to evaluate whether these antibodies (1) can serve as early detection markers, providing evidence of an immune response to a developing tumor, and (2) modify the discriminatory capacity of CA125 by either masking CA125 levels (resulting in lower discrimination) or acting synergistically to improve discrimination between cases and non-cases. We investigated these objectives using a nested case-control study within the European Prospective Investigation into Cancer and Nutrition cohort (EPIC) including 250 cases diagnosed within 4 years of blood collection and up to four matched controls. Circulating CA125 antigen and antibody levels were quantified using an electrochemiluminescence assay. Adjusted areas under the curve (aAUCs) by 2-year lag-time intervals were calculated using conditional logistic regression calibrated toward the absolute risk estimates from a pre-existing epidemiological risk model as an offset-variable. Anti-CA125 levels alone did not discriminate cases from controls. For cases diagnosed <2 years after blood collection, discrimination by CA125 antigen was suggestively higher with higher anti-CA125 levels (aAUC, highest antibody tertile: 0.84 [0.76-0.92]; lowest tertile: 0.76 [0.67-0.86]; phet = 0.06). We provide the first evidence of potentially synergistic discrimination effects of CA125 and anti-CA125 antibodies in ovarian early detection. If these findings are replicated, evaluating CA125 in the context of its antibody may improve ovarian cancer early detection.
000132470 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000132470 588__ $$aDataset connected to CrossRef, PubMed,
000132470 7001_ $$0P:(DE-He78)1bd6298f721e4a01f21c2329276a53a7$$aSchock, Helena$$b1$$udkfz
000132470 7001_ $$0P:(DE-He78)2d4cac0f4bf270325b98fe07036dc6c6$$aLe Cornet, Charlotte$$b2$$udkfz
000132470 7001_ $$0P:(DE-He78)6519c85d61a3def7974665471b8a4f74$$aHüsing, Anika$$b3$$udkfz
000132470 7001_ $$aVitonis, Allison F$$b4
000132470 7001_ $$aJohnson, Theron S$$b5
000132470 7001_ $$aFichorova, Raina N$$b6
000132470 7001_ $$aFashemi, Titilayo$$b7
000132470 7001_ $$aYamamoto, Hidemi S$$b8
000132470 7001_ $$aTjønneland, Anne$$b9
000132470 7001_ $$aHansen, Louise$$b10
000132470 7001_ $$aOvervad, Kim$$b11
000132470 7001_ $$aBoutron-Ruault, Marie-Christine$$b12
000132470 7001_ $$aKvaskoff, Marina$$b13
000132470 7001_ $$aSeveri, Gianluca$$b14
000132470 7001_ $$aBoeing, Heiner$$b15
000132470 7001_ $$aTrichopoulou, Antonia$$b16
000132470 7001_ $$aPapatesta, Eleni-Maria$$b17
000132470 7001_ $$00000-0003-1441-897X$$aLa Vecchia, Carlo$$b18
000132470 7001_ $$00000-0002-5558-2437$$aPalli, Domenico$$b19
000132470 7001_ $$aSieri, Sabina$$b20
000132470 7001_ $$aTumino, Rosario$$b21
000132470 7001_ $$00000-0002-8008-5096$$aSacerdote, Carlotta$$b22
000132470 7001_ $$aMattiello, Amalia$$b23
000132470 7001_ $$aOnland-Moret, N Charlotte$$b24
000132470 7001_ $$aPeeters, Petra H$$b25
000132470 7001_ $$aBueno-de-Mesquita, H B As$$b26
000132470 7001_ $$aWeiderpass, Elisabete$$b27
000132470 7001_ $$aQuirós, J Ramón$$b28
000132470 7001_ $$00000-0001-5256-0163$$aDuell, Eric J$$b29
000132470 7001_ $$aSánchez, Maria-Jose$$b30
000132470 7001_ $$aNavarro, Carmen$$b31
000132470 7001_ $$aArdanaz, Eva$$b32
000132470 7001_ $$aLarrañaga, Nerea$$b33
000132470 7001_ $$aNodin, Björn$$b34
000132470 7001_ $$aJirström, Karin$$b35
000132470 7001_ $$aIdahl, Annika$$b36
000132470 7001_ $$aLundin, Eva$$b37
000132470 7001_ $$aKhaw, Kay-Tee$$b38
000132470 7001_ $$aTravis, Ruth C$$b39
000132470 7001_ $$aGunter, Marc$$b40
000132470 7001_ $$aJohansson, Mattias$$b41
000132470 7001_ $$aDossus, Laure$$b42
000132470 7001_ $$aMerritt, Melissa A$$b43
000132470 7001_ $$aRiboli, Elio$$b44
000132470 7001_ $$aTerry, Kathryn L$$b45
000132470 7001_ $$aCramer, Daniel W$$b46
000132470 7001_ $$00000-0003-3751-3929$$aKaaks, Rudolf$$b47$$eLast author
000132470 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.31164$$gVol. 142, no. 7, p. 1355 - 1360$$n7$$p1355 - 1360$$tInternational journal of cancer$$v142$$x0020-7136$$y2018
000132470 909CO $$ooai:inrepo02.dkfz.de:132470$$pVDB
000132470 9101_ $$0I:(DE-588b)2036810-0$$60000-0002-1426-8505$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000132470 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1bd6298f721e4a01f21c2329276a53a7$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000132470 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2d4cac0f4bf270325b98fe07036dc6c6$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000132470 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6519c85d61a3def7974665471b8a4f74$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000132470 9101_ $$0I:(DE-588b)2036810-0$$60000-0003-3751-3929$$aDeutsches Krebsforschungszentrum$$b47$$kDKFZ
000132470 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000132470 9141_ $$y2018
000132470 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000132470 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000132470 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000132470 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000132470 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2015
000132470 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000132470 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000132470 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000132470 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000132470 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000132470 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000132470 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2015
000132470 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebserkrankungen$$x0
000132470 980__ $$ajournal
000132470 980__ $$aVDB
000132470 980__ $$aI:(DE-He78)C020-20160331
000132470 980__ $$aUNRESTRICTED